Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk factors associated with the development of HCC lead initially to liver cirrhosis, which can be found in the majority of HCC patients and remains the underlying disease in these patients. Using primary research conducted with expert , European, and Japanese HCC specialists, including gastroenterologists, hepatologists, and medical oncologists, this report provides a comprehensive analysis of the competitive landscape and market opportunity for HCC. It includes a comprehensive analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. HCC is potentially curable only when detected in its early stages and can be treated by tumor resection, tumor ablation, or liver transplantation. Current treatment options for advanced HCC are very limited, and only one targeted therapy, sorafenib (Bayer/Onyx’s Nexavar), is approved for treatment in this setting.
Questions Answered in This Report:
- HCC arises mainly in patients with underlying liver disease. What is the size of the U.S., EU5 (France, Germany, Italy, Spain, and United Kingdom), and Japanese HCC patient population, and how will it change over the ten-year forecast period (2013-2023)? What are the key HCC patient populations?
- Treatment of HCC must take into account underlying liver disease, which makes treatment of HCC highly complex. What type of practitioner assumes care of HCC patients, and does it differ depending on the stage of the disease and/or the geographical market? How are physicians currently managing treatment of HCC patients?
- Sorafenib is the only targeted therapy approved for treatment of HCC. How is sorafenib incorporated into the current treatment algorithm of HCC, and does it differ between the markets under study? Do we forecast that this use will change during our ten-year forecast period? What therapies in clinical development, if at any, pose a threat to sorafenib’s current positioning?
- We have identified several unmet needs, challenges, and opportunities in the HCC landscape. What are the key unmet needs in the treatment of HCC according to interviewed thought leaders? Is it likely that these unmet needs will be addressed or partially addressed during our forecast period?
- There are several therapies in later-stage clinical development for HCC. What do experts interviewed think about the prospects of these emerging therapies, especially in light of recent late-stage clinical trial failures for several agents that were in development for treatment of HCC? Which agents, if any, do we forecast will launch for treatment of HCC, and how, if at all, will such a launch impact the HCC landscape?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 10 country-specific interviews with thought leaders (gastroenterologists, hepatologists, and medical oncologists).
Epidemiology: Diagnosed incident cases of HCC by stage of disease. Clinical- and market-relevant drug-treatable populations.
Emerging therapies: Phase II: 12; Phase III/PR: 9.